Kinvard Bioo Secures $2.7M to Propel Breakthrough Ribosome-Targeting Antibiotics from Harvard Innovation

Kinvard Bio is excited to announce a successful funding round in which the company raised $2,700,000. This significant injection of capital reinforces our mission to develop a new, highly differentiated class of ribosome-targeting antibiotics designed to combat acute and chronic drug-resistant bacterial infections. At the core of our innovative approach is our groundbreaking chemistry platform technology, based on exclusive research licensed from the prestigious Myers lab at the Department of Chemistry and Chemical Biology at Harvard University. The work behind our platform has been further supported by the Kineticos AMR Accelerator Fund I (KAMRA I), ensuring our research continues to push boundaries and pave the way for novel therapeutic solutions. We are leveraging the funds to advance the preclinical development of our distinctive class of oxepanoprolinamides (OPPs), a unique line of lincosamide antibiotics that are purposefully pre-organized to bind effectively and selectively to the bacterial ribosome. Early studies have demonstrated that our OPPs show promising efficacy against a spectrum of Gram-positive and Gram-negative bacterial pathogens, particularly those linked with high unmet clinical needs. This progress not only has strong scientific implications but also holds substantial commercial potential for addressing the growing global threat of antibiotic resistance. The newly secured funding will enable us to accelerate our research and development initiatives, optimize our molecular designs, and further refine our formulations through rigorous preclinical testing. Overall, this investment marks an important milestone that will help propel Kinvard Bio to the forefront of innovation in the fight against drug-resistant infections, while reinforcing our commitment to transforming pioneering scientific research into tangible clinical solutions.